<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="utf-8">

  <title>NICE Formulary - TOPIRAMATE</title>

  <meta name="X-UA-Compatible" content="IE=edge,chrome=1">
  <meta name="viewport" content="width=device-width, initial-scale=1.0, maximum-scale=1.0">
  <meta name="description" content="">
  <meta name="author" content="NICE - The National Institute of Health and Care Excellence">

  <!--[if lt IE 9]>
  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/html5shiv.js"></script>
  <![endif]-->

  <!-- Le styles -->
  <link rel="stylesheet" href="http://mattonfoot.github.io/NICE.UI/styles/ui.css">

  <!-- Fav and touch icons -->
  <link rel="shortcut icon" href="http://cdn.nice.org.uk/V3/Content/nice/favicon.ico">
  <link rel="apple-touch-icon-precomposed" href="http://cdn.nice.org.uk/V3/Content/nice/favicon-152.png">
  <meta name="msapplication-TileColor" content="#fafafb">
  <meta name="msapplication-TileImage" content="http://cdn.nice.org.uk/V3/Content/nice/favicon-144.png">

  <style>
  .tab-content {
    overflow: auto;
  }
  .tab-content > .tab-pane {
    display: none;
  }
  .tab-content > .active {
    display: block;
  }

  header .nav {
    list-style: decimal inside none;
  }
  header .nav > li {
    display: list-item;
  }
  header .nav > li > a {
    display: block;
    margin: 0;
    padding: 0;
    text-decoration: none;
    color: #01769d;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus,
  header .nav > li.active > a,
  header .nav > li.active > a:hover,
  header .nav > li.active > a:focus {
    outline: 0;
    color: #08455b;
    background: transparent;
    text-decoration: none;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus {
    text-decoration: underline;
  }

  [outputclass="title"],
  .title {
    font-size: 19px;
    font-size: 1.9rem;
    line-height: 24px;
    line-height: 2.4rem;
  }

  h3, h4, h5, h6, .title, [outputclass="title"] {
    margin-bottom: 0;
  }

  h1+p, h2+p, h3+p, h4+p, h5+p, h6+p, .title+p, [outputclass="title"]+p {
    margin-top: 0;
  }

  .doses {
    padding-left: 0;
    list-style: none;
  }
  .doses .dose {
    padding-left: 24px;
    padding-left: 2.4rem;
    margin-bottom: 6px;
    margin-bottom: .6rem;
  }
  .doses .adult {
    border-left: 7px solid #346e7f;
  }
  .doses .child {
    border-left: 7px solid #82176F;
  }

  /* DITA symbols */

  ph {
    color: #006;
  }

  tm::before {
    font-size: .8em;
    margin-left: -.2em;
    vertical-align: top;
  }
  tm[tmtype="reg"]::before {
    content: "\00ae";
  }
  tm[tmtype="copy"]::before {
    content: "\00a9";
  }
  tm[tmtype="trade"]::before {
    content: "\2122";
  }

  </style>
</head>

<body id="" class="">
  <header>
    <div class="container">
      <ul class="breadcrumb">
        <li><a href="../">Home</a> <span class="divider glyph-chevron-right"></span></li>
        <li class="active"><a href="../drug/">Drugs</a></li>
      </ul>

      <h1>TOPIRAMATE</h1>


      <nav>
        <ul class="nav nav-list">

          <li class="active"><a href="#indicationsAndDoses" data-toggle="tab">Indications and doses</a></li>
          <li><a href="#pregnancy" data-toggle="tab">Pregnancy</a></li>
          <li><a href="#hepaticImpairment" data-toggle="tab">Hepatic impairment</a></li>
          <li><a href="#renalImpairment" data-toggle="tab">Renal impairment</a></li>
          <li><a href="#sideEffects" data-toggle="tab">Side effects</a></li>
          <li><a href="#directionsForAdministration" data-toggle="tab">Administration</a></li>
          <li><a href="#patientAndCarerAdvice" data-toggle="tab">Patient and carer advice</a></li>
          <li><a href="#cautions" data-toggle="tab">Cautions</a></li>
          <li><a href="#unlicensedUse" data-toggle="tab">Unlicensed use</a></li>
          <li><a href="#prescribingAndDispensingInformation" data-toggle="tab">Prescribing and dispensing</a></li>
          <li><a href="#medicinalForms" data-toggle="tab">Medicinal forms</a></li>
        </ul>
      </nav>

      <br/>
    </div>
  </header>

  <div class="container">
    <div class="tab-content">

      <section class="tab-pane active" id="indicationsAndDoses">
        <h2>Indications and doses</h2>

        <section class="indicationAndDoseGroups">
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Monotherapy of generalised tonic-clonic seizures or focal seizures with or without secondary generalisation</span>,
            </h4>
            <p class="specificity"><span class="route">By mouth</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                Initially 25 mg once daily for 1 week, dose to be taken at night, then increased in steps of 25&#8211;50 mg every 1&#8211;2 weeks, dose to be taken in 2 divided doses; usual dose 100&#8211;200 mg daily in 2 divided doses, adjusted according to response, doses of 1 g daily have been used in refractory epilepsy; maximum 500 mg per day.</li>
              <li class="dose child"><strong>For children 6&#8211;17 years</strong><br/>
                Initially 0.5&#8211;1 mg/kg once daily (max. per dose 25 mg) for 1 week, dose to be taken at night, then increased in steps of 250&#8211;500 micrograms/kg twice daily, dose to be increased by a maximum of 25 mg twice daily at intervals of 1&#8211;2 weeks; usual dose 50 mg twice daily (max. per dose 7.5 mg/kg twice daily), if child cannot tolerate titration regimens recommended above then smaller steps or longer interval between steps may be used; maximum 500 mg per day.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Adjunctive treatment of generalised tonic-clonic seizures or focal seizures with or without secondary generalisation</span>,
                <span class="indication">Adjunctive treatment for seizures associated with Lennox-Gastaut syndrome</span>,
            </h4>
            <p class="specificity"><span class="route">By mouth</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                Initially 25&#8211;50 mg once daily for 1 week, dose to be taken at night, then increased in steps of 25&#8211;50 mg every 1&#8211;2 weeks, dose to be taken in 2 divided doses; usual dose 200&#8211;400 mg daily in 2 divided doses; maximum 400 mg per day.</li>
              <li class="dose child"><strong>For children 2&#8211;17 years</strong><br/>
                Initially 1&#8211;3 mg/kg once daily (max. per dose 25 mg) for 1 week, dose to be taken at night, then increased in steps of 0.5&#8211;1.5 mg/kg twice daily, dose to be increased by a maximum of 25 mg twice daily at intervals of 1&#8211;2 weeks; usual dose 2.5&#8211;4.5 mg/kg twice daily (max. per dose 7.5 mg/kg twice daily), if child cannot tolerate recommended titration regimen then smaller steps or longer interval between steps may be used; maximum 400 mg per day.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Migraine prophylaxis</span>,
            </h4>
            <p class="specificity"><span class="route">By mouth</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                Initially 25 mg once daily for 1 week, dose to be taken at night, then increased in steps of 25 mg every 1 week; usual dose 50&#8211;100 mg daily in 2 divided doses; maximum 200 mg per day.</li>
            </ul>
          </section>
        </section>
        
        
        
        
        
      </section>



      <section class="tab-pane" id="pregnancy">
        <h2>Advice when patient is pregnant</h2>

            <section class="generalInformation">
              <p>Increased risk of cleft palate if taken in the first trimester of pregnancy.</p>
            </section>
      </section>

      <section class="tab-pane" id="hepaticImpairment">
        <h2>Advice regarding hepatic impairment</h2>

            <section class="generalInformation">
              <p>Use with caution in moderate to severe impairment&#8212;clearance may be reduced.</p>
            </section>
      </section>

      <section class="tab-pane" id="renalImpairment">
        <h2>Advice regarding renal impairment</h2>

            <section class="doseAdjustments">
              <h3 class="specificity">In adults</h3>
              <p>Half usual starting and maintenance dose if eGFR less than 70&#8239;mL/ minute/1.73&#8239;m<sup>2</sup>&#8212;reduced clearance and longer time to steady-state plasma concentration.</p>
            </section>
            <section class="doseAdjustments">
              <h3 class="specificity">In children</h3>
              <p>Half usual starting and maintenance dose if estimated glomerular filtration less than 70&#8239;mL/ minute/1.73&#8239;m<sup>2</sup>&#8212;reduced clearance and longer time to steady-state plasma concentration.</p>
            </section>
        
            <section class="generalInformation">
              <p>Use with caution.</p>
            </section>
      </section>


      <section class="tab-pane" id="sideEffects">
        <h2>Known side effects</h2>

          <h3>General side effects</h3>
              <p>
                <strong>commonOrVeryCommon:</strong> Abdominal pain, aggression, agitation, alopecia, anaemia, anxiety, appetite changes, arthralgia, cognitive impairment, confusion, constipation, depression, diarrhoea, dizziness, drowsiness, dry mouth, dyspepsia, dyspnoea, epistaxis, gastritis, impaired attention, impaired coordination, irritability, malaise, mood changes, movement disorders, muscle spasm, muscular weakness, myalgia, nausea, nephrolithiasis, nystagmus, paraesthesia, pruritus, rash, seizures, sleep disturbance, speech disorder, taste disturbance, tinnitus, tremor, urinary disorders, visual disturbances, vomiting,
              </p>
              <p>
                <strong>uncommon:</strong> Abdominal distension, altered sense of smell, blepharospasm, blood disorders, bradycardia, dry eye, flatulence, flushing, gingival bleeding, glossodynia, haematuria, halitosis, hearing loss, hypokalaemia, hypotension, increased lacrimation, influenza-like symptoms, leucopenia, metabolic acidosis, mydriasis, neutropenia, palpitation, pancreatitis, panic attack, peripheral neuropathy, photophobia, postural hypotension, psychosis, reduced sweating, salivation, sexual dysfunction, skin discoloration, suicidal ideation, thirst, thrombocytopenia, urinary calculus,
              </p>
              <p>
                <strong>rare:</strong> Abnormal skin odour, calcinosis, hepatic failure, hepatitis, periorbital oedema, Raynaud&#8217;s syndrome, Stevens-Johnson syndrome, unilateral blindness,
              </p>
              <p>
                <strong>veryRare:</strong> Angle-closure glaucoma,
              </p>
              <p>
                <strong>notKnown:</strong> Encephalopathy, hyperammonaemia, maculopathy, toxic epidermal necrolysis,
              </p>
        
        
            <section class="advice">
                <h3>Acute myopia with secondary angle-closure glaucoma</h3>
              <p>Topiramate has been associated with acute myopia with secondary angle-closure glaucoma, typically occurring within 1 month of starting treatment. Choroidal effusions resulting in anterior displacement of the lens and iris have also been reported. If raised intra-ocular pressure occurs:</p><ul>
            <li>seek specialist ophthalmological advice;</li>
            <li>use appropriate measures to reduce intra-ocular pressure;</li>
            <li>stop topiramate as rapidly as feasible</li>
            </ul>
            </section>
        
      </section>

      <section class="tab-pane" id="directionsForAdministration">
        <h2>Directions for administration</h2>

            <section class="directionsForAdministration">
              <p>
            <i>Topamax</i>
            <tm tmtype="reg"/>
            <i>Sprinkle</i> capsules can either be swallowed whole or the contents of the capsule can be sprinkled on soft food and swallowed immediately without chewing.</p>
            </section>
      </section>

      <section class="tab-pane" id="patientAndCarerAdvice">
        <h2>Advice for patients and carers</h2>

            <section class="generalPatientAdvice">
              <p>Patients should be counselled on the administration of <i>Topamax</i>
            <tm tmtype="reg"/>
            <i>Sprinkle</i> capsules.</p>
            </section>
            <section class="patientResources">
              <h3 class="specificity">In children</h3>
                <p class="title">Medicines for Children leaflet: Topiramate for preventing seizures</p>
              <p>
            <xref format="html" href="http://www.medicinesforchildren.org.uk/topiramate-for-preventing-seizures">www.medicinesforchildren.org.uk/topiramate-for-preventing-seizures</xref>
            </p>
            </section>
      </section>



      <section class="tab-pane" id="cautions">
        <h2>Cautions regarding administration</h2>

        <ul>
          <li>
            Avoid in <xref format="dita" href="#PHP78608" type="bookmark" namespace="/treatment-summaries/acute-porphyrias">Acute porphyrias</xref>
          </li>
          <li>
            risk of metabolic acidosis
          </li>
          <li>
            risk of nephrolithiasis&#8212;ensure adequate hydration (especially in strenuous activity or warm environment)
          </li>
        </ul>
      </section>



      <section class="tab-pane" id="unlicensedUse">
        <h2>Unlicensed use</h2>

            <section class="unlicensedUse">
              <h3 class="specificity">In children</h3>
              <p>Not licensed for use in children for migraine prophylaxis.</p>
            </section>
      </section>

      <section class="tab-pane" id="prescribingAndDispensingInformation">
        <h2>Information regarding prescribing and dispensing</h2>

            <section class="prescribingAndDispensingInformation">
                <h3>Switching between formulations</h3>
              <p>Care should be taken when switching between oral formulations in the treatment of epilepsy. The need for continued supply of a particular manufacturer's product should be based on clinical judgement and consultation with the patient or their carer, taking into account factors such as seizure frequency and treatment history.</p><p>Patients being treated for epilepsy may need to be maintained on a specific manufacturer&#8217;s branded or generic topiramate product.</p>
            </section>
      </section>









      <section class="tab-pane" id="medicinalForms">
        <h2>Prepared medicinal forms of TOPIRAMATE</h2>


            <section class="licensingVariationStatement">
              <p>There can be variation in the licensing of different medicines containing the same drug.</p>
            </section>
        
          <strong>Forms available from special-order manufacturers include: </strong>
            oral solution,
            oral suspension,

            <div id="PHP76155"><a href="../medicinalForm/PHP76155.html" data-target="#PHP76155" data-action="load">Tablet</a></div>
            <div id="PHP76162"><a href="../medicinalForm/PHP76162.html" data-target="#PHP76162" data-action="load">Capsule</a></div>
      </section>
    </div>
  </div>

  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/jquery.js"></script>
  <script src="http://cdn.nice.org.uk/V3/Scripts/twitter.bootstrap.js"></script>
  <script src="/content/scripts/NICE.RemoteLoad.js"></script>
</html>
